Product Name: IGF1R (1343-1349) pY1346
Product Number: PE-04AKL99
Size: 200 µg      Price:47.00
1 mg      $US94.00
5 mg      206.00
Peptide Name: IGF1R (1343-1349) pY1346

Product Use: Services as a blocking peptide for use with the IGF1R-pY1346 rabbit polyclonal antibody (Cat. No.: AB-PK658) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the C-terminal of the kinase after the catalytic domain. Y1346 phosphorylation stimulates phosphotransferase activity and induces binding to Grb10. Phosphorylation regulates cell differentiation, cell growth, molecular association and protein interaction.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: RQP-pY-AHM

Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys

Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1156.23 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: IGF1R - pY1346 phosphosite-specific antibody (Cat. No.: AB-PK658)

Scientific Background: IGF1R is a protein-tyrosine kinase of the TK group and InsR family. It mediates the effects of its ligand insulin-like growth factor 1 (IGF1) to promote cell growth and survival. The pre-dimerized receptor also displays weak affinity for both insulin and IGF2. Once ligand bound, the IGF1R undergoes autophosphorylation and activates several downstream signalling pathways, including the PI3K-Akt pathway and the Ras/Raf/MAP kinase pathway to induce cell growth and survival. Autophosphorylation Y1161 and Y346 increases its phosphotransferase activity and induces interaction with Src. Y1346 autophosphorylation also mediates GRB10 binding to IGF1R. Y980, Y1161, Y1165 and Y1166 autophosphorylation also increases its phosphotransferase activity. Y980 autophosphorylation also appears to mediate IRS1 or Shc1 interactions with IGF1R. IGFR1 is an oncoprotein (OP). Cancer-related mutations in human tumours point to a gain of function of the protein kinase. The active form of the protein kinase normally acts to promote tumour cell proliferation. IGF1R been shown to be an important signalling component in several types of human cancers. In particular, the activated receptor is critical for tumour transformation, malignant cell survival, and the maintenance of the transformed phenotype. In addition, activated IGF1R protein functions to inhibit apoptosis via indirect phosphorylation of the BAD protein via Akt, as well as plays an important role in the regulation of cancer cell motility and metastasis. Several cancer types display increased expression of IGF1R and/or increased catalytic activity of the protein, including prostate cancer, colorectal adenoma, and melanoma. Additionally, cross-talk between the IGF signalling pathway and the estrogen receptor signalling pathway has been demonstrated in breast cancer cells as a central mechanism of cell growth regulation. Furthermore, therapies aimed at the inhibition of IGF1R signalling have shown promise as potential cancer treatments. Insertional mutagenesis studies in mice support a role for this protein kinase in mouse cancer oncogenesis.